Here’s a startling revelation: popular weight-loss and diabetes medications like Ozempic and Wegovy might come with a hidden cost—an increased risk of osteoporosis and gout. But here’s where it gets controversial: while these drugs have transformed lives, new research suggests they could be silently weakening bones and triggering joint pain. Should we rethink their use? Let’s dive in.
Presented at the American Academy of Orthopaedic Surgeons’ annual meeting, a groundbreaking study led by Dr. John Horneff from the University of Pennsylvania has uncovered a potential link between GLP-1 drugs and these serious health concerns. Horneff’s investigation began with a puzzling observation: patients on these medications were experiencing severe tendon tears from seemingly minor injuries. This led his team to explore whether GLP-1s might have broader effects on bone and connective tissue.
And this is the part most people miss: while GLP-1s are celebrated for their weight-loss benefits, they also suppress appetite, which can lead to reduced nutrient intake. Horneff explains, ‘People are taking these medications, and there’s a tremendous upside, but they start to decrease their intake of food and nutrients.’ This reduction could be a silent contributor to bone health issues.
Osteoporosis, a condition that weakens bones and makes them prone to fractures, is often associated with aging or rapid weight loss. Gout, a painful form of arthritis, can flare up due to high uric acid levels, which are linked to diets rich in red meat and alcohol—or, surprisingly, rapid weight loss. The study analyzed five years of medical records from over 146,000 adults with obesity and Type 2 diabetes, comparing GLP-1 users to nonusers.
The findings? GLP-1 users had a 30% higher risk of osteoporosis (4% vs. 3% in nonusers) and a 12% higher risk of gout (7.4% vs. 6.6%). Even more alarming, the risk of bone mineral density issues nearly doubled over five years. Dr. Clifford Rosen, a bone health expert, notes, ‘Weight loss does cause bone loss, but the question is whether this is a normal skeletal adjustment or an accelerated risk.’
Here’s the kicker: while the study is observational and can’t prove causation, it aligns with other research, including a February study linking GLP-1s to higher fracture risks in older adults. The FDA even warns of potential bone fracture risks in its semaglutide label. But not everyone agrees. Dr. Susan Spratt points out that some studies suggest musculoskeletal benefits from GLP-1s, though she acknowledges joint health and bone density are distinct.
So, what’s really going on? One theory is that reduced nutrient intake—like vitamin D and calcium—could weaken bones. Another is that rapid weight loss alters how the body builds and breaks down bone tissue. Horneff draws a fascinating parallel: ‘It’s like astronauts in zero gravity losing bone density because their bones aren’t bearing weight. Similarly, rapid weight loss might disrupt the skeleton’s adaptation.’
For gout, rapid weight loss can temporarily spike uric acid levels, increasing risk. But Dr. Christopher McGowan offers a glimmer of hope: combining GLP-1s with structured exercise can mitigate bone density loss. ‘Lifestyle factors play a major role,’ he emphasizes. His takeaway? ‘The goal isn’t fear—it’s refinement.’
Now, the big question: Do the benefits of GLP-1s outweigh these risks? Should patients be more closely monitored for bone and joint health? Share your thoughts in the comments—this is a conversation that needs your voice!
